RK

Rupam Kumari

Active Director Director DIN 11134802
DIN 11134802 First appointment Jun 2025 Primary industry Paper
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Jun 2025
Shareholding value •••• Premium profile

About Rupam Kumari

Data last updated:

Rupam Kumari is a Director at Pharmestra Biotech Private Limited (since 2025). The company operates in Paper. Pharmestra Biotech Private Limited reported revenue of ₹9 Lakh (FY 2024).

DIN 11134802
Primary Designation Director
Industry Paper
First Appointment 02 Jun 2025
Oldest Company Age 3 yrs
Largest company Pharmestra Biotech Private Limited · ₹9 Lakh (FY 2024)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Pharmestra Biotech Private Limited U21002DL2023PTC416849
Director02 Jun 20252023₹9 Lakh (FY 2024)Active

Board colleagues of Rupam Kumari

Directorship timeline

Open interactive timeline →
Pharmestra Biotech Private Limited
Premium access

Shareholding and investment profile for Rupam Kumari

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Rupam Kumari

Rupam Kumari currently holds 1 directorship: Pharmestra Biotech Private Limited (Director, since 02 Jun 2025, revenue ₹9 Lakh (FY 2024)).

Rupam Kumari was first appointed on 02 Jun 2025 as Director at Pharmestra Biotech Private Limited.

The current boards of Rupam Kumari's companies include Rajesh Kumar (Pharmestra Biotech Private Limited), Sujata Kumari (Pharmestra Biotech Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available